ResearchAndMarkets.com has added the Bi/Multispecific Drugs in Oncology Analytical Tool and the Cancer Vaccines Analytical Tool to its offering, each providing one year of online access to continuously updated competitive, clinical and business intelligence. During 2024/25, the bi- and multispecific oncology landscape added 278 new drugs and recorded more than 8,566 events across 2,120 drug programs, while 2024 and 2025 cancer vaccine activity included 76 new vaccines and 1,946 events across 1,412 drug programs. The platforms track organizations, candidates, targets, technologies, biomarkers, trials, combination therapies, licensing, funding, investors and commercial opportunities, with exportable reports, monthly alerts, training and 24/7 support. Users can renew access or upgrade to 1stOncology, a broader oncology intelligence platform.